- 43.8% of patients with nonendometrioid endometrial cancer do not receive guideline-concordant treatment.
- Guideline-recommended treatment is associated with improved OS in patients of all ethnicities except Asian/Pacific Islander.
Why this matters
- Guideline-concordant treatment adherence interventions may improve survival, and barriers to adherence should be identified and addressed.
- Study of 30,426 women with nonendometrioid endometrial cancer during 2004-2014.
- Year-specific National Comprehensive Cancer Network guidelines were used to classify treatment.
- Funding: National Cancer Institute.
- 43.8% of women received guideline-concordant treatment.
- Guideline-concordant treatment did not differ with race/ethnicity (P=.46).
- Guideline-concordant treatment was associated with improved OS (HR, 0.85; 95% CI, 0.82-0.87):
- Non-Hispanic whites (n=21,177): HR, 0.84 (95% CI, 0.80-0.87).
- Non-Hispanic blacks (n=6657): HR, 0.85 (95% CI, 0.80-0.91).
- Hispanic (n=1689): HR, 0.84 (95% CI, 0.72-0.98).
- Survival advantage was not reported in Asian/Pacific Islander patients (n=903) with guideline-concordant treatment.
- Observational study.